DV
Dividend Vision

LSTA — Lisata Therapeutics Inc.

Lisata Therapeutics Inc. (LSTA)

Its deepest 1-year drawdown was 80.4%.

Lisata Therapeutics is a clinical-stage pharmaceutical company developing therapies for solid tumors and other diseases, with its lead candidate certepetide currently in Phase 2 clinical studies for metastatic pancreatic cancer, cholangiocarcinoma, appendiceal cancer, colon cancer, and glioblastoma multiforme. The company does not currently distribute dividends. Lisata appeals primarily to investors seeking exposure to early-stage oncology drug development rather than those focused on current income.

LSTA key facts

Asset type
Stock
Asset class
Equity
Inception date
11/05/1984
Last close
$1.09
Market cap
$20,398,316
Average volume
24984.0
Beta
0.795
Payout ratio
0.0
Forward P/E
2.7093
EPS
$-1.18